AcquisitionsMay 18, 2026, 07:12 AM
Artivion Completes Endospan Acquisition for $131.3M Net Cash
AI Summary
Artivion, Inc. has completed its acquisition of Endospan Ltd., an Israeli company specializing in aortic instability products, including the Nexus™ system. The net cash purchase price was approximately $131.3 million, funded by a previously drawn $150 million delayed draw term loan. The deal also includes potential contingent consideration of up to $200 million based on the future performance of the Nexus™ product. This acquisition strategically enhances Artivion's aortic arch portfolio, especially following the Nexus™ system's U.S. FDA PMA approval in April 2026.
Key Highlights
- Artivion completed the acquisition of Endospan Ltd. on May 18, 2026.
- The net cash purchase price paid was approximately $131.3 million.
- The acquisition was funded by a previously drawn $150 million delayed draw term loan.
- Up to $200 million in contingent consideration is possible based on Nexus™ product performance.
- $16.5 million was deposited into an indemnity escrow fund.
- $1.0 million was deposited into an adjustment escrow fund.
- Endospan's Nexus™ system received U.S. FDA PMA approval in April 2026.
- The acquisition completes Artivion's market-leading aortic arch portfolio.
Price Impact
More from AORT